BizToc

[ad_1]

On Thursday, Immuneering Corporation (NASDAQ:IMRX) released initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer as part of its ongoing Phase 2a trial.
The first two patients in the Phase…

[ad_2]